Navigation Links
Beyond the Failed Beta Amyloid Hypothesis -- Alzheimer's Experts to Discuss Need for New Medicines with Alternative Mechanisms of Action in Pre-CTAD Conference Webinar Tomorrow
Date:12/5/2016

BOULDER, Colo., Nov. 29, 2016 /PRNewswire/ -- Several leading Alzheimer's disease experts will participate in a webinar hosted by Accera, Inc. at 11 a.m. EST on December 6 in advance of the 9th Annual International Conference on Clinical Trials for Alzheimer's Disease (CTAD). The program will include discussions on the role of metabolism in Alzheimer's disease and therapeutic targets that address deficient glucose metabolism observed in Alzheimer's disease patients.

"Following the recent failure of another therapy targeting the amyloid hypothesis, now more than ever we need to focus on alternative mechanisms to address Alzheimer's disease," said Michael Gold, M.D., Accera's senior medical advisor and the moderator of the webinar. "As the Alzheimer's community prepares to gather for CTAD, we want to provide perspectives from researchers leading the way to address the fundamental metabolic defect in Alzheimer's patients."

Dr. Gold will moderate a discussion following presentations by:

Dr. Swerdlow will present information about the history of the metabolic hypothesis and the role of mitochondrial defects in Alzheimer's disease. He is the Director of the University of Kansas Alzheimer's Disease Center and the KUMC Neurodegenerative Disorders Program. Dr. Swerdlow is a Professor in the Departments of Neurology, Molecular and Integrative Physiology, and Biochemistry and Molecular Biology at the University of Kansas School of Medicine. After receiving his undergraduate and doctor of medicine degrees from New York University, he trained as a neurologist and cognitive disorders subspecialist at the University of Virginia. Dr. Swerdlow sees patients at the University of Kansas Memory Disorders Clinic and is a laboratory-based neuroscientist who is internationally known for his work on mitochondrial dysfunction in neurodegenerative diseases.

Dr. Trushina will present information on emerging mitochondria-targeted therapeutics. Her laboratory is focused on mitochondrial dysfunction caused by environmental toxins, chemotherapy drugs and genetic factors in multiple neurodegenerative disorders, including Huntington's disease and Alzheimer's disease, aging, and chemotherapy-induced peripheral neuropathy. Her research interests involve identification of the molecular mechanisms involved in the inhibition of mitochondrial dynamics and function in neurons. Dr. Trushina's current projects include the development of a panel of the biomarkers associated with mitochondrial dysfunction involved in neurodegeneration and testing novel mitochondria-targeted therapeutic approaches that could potentially reverse neurodegeneration and aging. Dr. Trushina has a Ph.D. from Saratov State University in Russia and conducted postdoctoral studies at the Mayo Clinic College of Medicine. Dr. Trushina's research has been funded by the Mayo Clinic Alzheimer's Disease Research Center, the American Health Assistance Foundation, the Alzheimer Drug Discovery Foundation and the National Institutes of Health.

Accera's lead product candidate, AC-1204, addresses the issue of deficient glucose metabolism in Alzheimer's disease by inducing a mild form of ketosis by generating ketones for use in neurons. These ketones have the potential to restore the supply of energy, improving neuronal metabolism and in turn cognition and function in patients with mild to moderate Alzheimer's disease. AC-1204 is currently being evaluated in a double-blind, placebo-controlled Phase 3 study called NOURISH AD. Results from this study are expected in the coming months.

Webinar Information

Participants can register in advance and access the webinar by clicking the following link: https://www.webcaster4.com/Webcast/Page/1588/18619. Participants are encouraged to log on within 15 minutes prior to the beginning of the webinar. Following the event, a replay will be available at the same link and on the Accera website.

About Accera

Accera, Inc. is a clinical-stage biotechnology company based in Boulder, Colo., that is developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease. For more information, visit www.accerapharma.com.

Follow Accera on Twitter at twitter.com/accerainc.

Accera Media Contacts:                                                     

Russo Partners LLC

Todd Davenport, Ph.D.
(212) 845-4235                                                          
todd.davenport@russopartnersllc.com

Rich Allan                                                                  
(646) 942-5588
rich.allan@russopartnersllc.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/beyond-the-failed-beta-amyloid-hypothesis----alzheimers-experts-to-discuss-need-for-new-medicines-with-alternative-mechanisms-of-action-in-pre-ctad-conference-webinar-tomorrow-300373034.html


'/>"/>
SOURCE Accera, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
2. MD&M Minneapolis Conference Returns, October 28-30, With a Cutting-Edge Tailored Program Addressing the Most Critical Challenges for the Medical Devices Industry for 2013 and Beyond
3. Achieve Beyond Pediatric Therapy Offers Exciting CEU Workshop in Virginia
4. Beyond the Headlines: What the FDA Decisions on Extended-release and Long-Acting Opioids Mean for People With Pain
5. Beyond BMI - the New seca medical Body Composition Analyzer
6. The Approval Of The First Biosimilar Monoclonal Antibody In Europe Has Major Implications For 2014 And Beyond
7. Cochlear Launches New York City Hearing Awareness Initiative Aimed at Educating the Public About Solutions Beyond Hearing Aids
8. Futuristic Technologies That Will Transform Our World Beyond 2030
9. Consilium Strategic Communications and Covington & Burling LLP to Host 2014 Annual Healthcare Conference "The Future of Healthcare - Funding Options, Innovation and M&A for 2015 and Beyond"
10. Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information
11. Sri Lanka Pharma Market Outlook 2015: More Beyond Importers & Distributors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)...  Eli Lilly and Company (NYSE: LLY ... quarter of 2017 on Tuesday, October 24, 2017. Lilly ... with the investment community and media to further detail ... will begin at 9 a.m. Eastern time. Investors, media ... of the conference call through a link that will ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
Breaking Medicine Technology:
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
Breaking Medicine News(10 mins):